Leanne Berry

2.4k total citations
24 papers, 1.7k citations indexed

About

Leanne Berry is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Leanne Berry has authored 24 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Leanne Berry's work include Melanoma and MAPK Pathways (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and HER2/EGFR in Cancer Research (5 papers). Leanne Berry is often cited by papers focused on Melanoma and MAPK Pathways (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and HER2/EGFR in Cancer Research (5 papers). Leanne Berry collaborates with scholars based in United States, Germany and France. Leanne Berry's co-authors include Lori S. Friedman, Marcia Belvin, Carol O’Brien, Mark R. Lackner, Klaus P. Hoeflich, Lukas C. Amler, Heidi Savage, Elizabeth A. Punnoose, Deepak Sampath and Lesley Murray and has published in prestigious journals such as Blood, Cancer Cell and Cancer Research.

In The Last Decade

Leanne Berry

22 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leanne Berry United States 14 1.2k 715 268 267 182 24 1.7k
Jose Lobo United States 8 1.2k 1.0× 758 1.1× 276 1.0× 180 0.7× 236 1.3× 8 1.6k
Teresa Klinowska United Kingdom 22 1.3k 1.0× 717 1.0× 419 1.6× 252 0.9× 99 0.5× 62 2.0k
Yasir H. Ibrahim United States 12 1.1k 0.9× 828 1.2× 305 1.1× 249 0.9× 126 0.7× 22 1.6k
Matthias Drosten Spain 22 1.4k 1.2× 777 1.1× 261 1.0× 291 1.1× 301 1.7× 43 2.0k
Ngocdiep T. Le United States 12 1.3k 1.0× 1.1k 1.5× 302 1.1× 346 1.3× 252 1.4× 29 1.9k
Michiya Nishino United States 18 888 0.7× 720 1.0× 327 1.2× 271 1.0× 312 1.7× 63 2.0k
Cornelia Quadt Switzerland 25 1.4k 1.2× 756 1.1× 591 2.2× 273 1.0× 208 1.1× 53 2.2k
Jiang Shou United States 15 1.4k 1.1× 1.3k 1.8× 352 1.3× 524 2.0× 81 0.4× 20 2.4k
Nandini Dey United States 25 1.4k 1.2× 907 1.3× 365 1.4× 432 1.6× 183 1.0× 71 2.1k
Malte Peters United States 9 1.6k 1.3× 899 1.3× 332 1.2× 288 1.1× 253 1.4× 12 2.2k

Countries citing papers authored by Leanne Berry

Since Specialization
Citations

This map shows the geographic impact of Leanne Berry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leanne Berry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leanne Berry more than expected).

Fields of papers citing papers by Leanne Berry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leanne Berry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leanne Berry. The network helps show where Leanne Berry may publish in the future.

Co-authorship network of co-authors of Leanne Berry

This figure shows the co-authorship network connecting the top 25 collaborators of Leanne Berry. A scholar is included among the top collaborators of Leanne Berry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leanne Berry. Leanne Berry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rauch, Sebastian, Massimo Pregnolato, Leanne Berry, et al.. (2024). 116 (PB104): Preclinical characterization of SKY-1214, a small molecule splicing modulator of Fanconi Anemia pathway members for the treatment of multiple myeloma and non-Hodgkin’s lymphoma. European Journal of Cancer. 211. 114639–114639. 1 indexed citations
3.
Scales, Suzie J., Nidhi Gupta, Glenn Pacheco, et al.. (2014). Abstract 4494: A clinical candidate anti-mesothelin-MMAE antibody-drug conjugate (ADC) for therapy of mesothelin-expressing cancers. Cancer Research. 74(19_Supplement). 4494–4494. 1 indexed citations
4.
Munugalavadla, Veerendra, Sanjeev Mariathasan, Dionysos Slaga, et al.. (2013). The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene. 33(3). 316–325. 37 indexed citations
5.
Klinger, Bertram, Anja Sieber, Raphaela Fritsche‐Guenther, et al.. (2013). Network quantification of EGFR signaling unveils potential for targeted combination therapy. Molecular Systems Biology. 9(1). 673–673. 119 indexed citations
6.
Wallin, Jeffrey J., Jane Guan, Wei Wei Prior, et al.. (2012). GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo. Clinical Cancer Research. 18(14). 3901–3911. 73 indexed citations
7.
Choo, Edna F., Chee M. Ng, Leanne Berry, et al.. (2012). PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemotherapy and Pharmacology. 71(1). 133–143. 26 indexed citations
8.
Hoeflich, Klaus P., Mark Merchant, Christine Orr, et al.. (2011). Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition. Cancer Research. 72(1). 210–219. 200 indexed citations
9.
Tan, Nguyen, Jiping Zha, Yue Peng, et al.. (2011). Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models. Clinical Cancer Research. 17(6). 1394–1404. 83 indexed citations
10.
Wilson, Timothy R., Diana Lee, Leanne Berry, David S. Shames, & Jeff Settleman. (2011). Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers. Cancer Cell. 20(2). 158–172. 125 indexed citations
11.
Smyczek, Tanya, Jason Cheng, Rafael Molina, et al.. (2011). Abstract 3295: Inhibiting vascular morphogenesis in tumors: EGFL7 as a novel therapeutic target. Cancer Research. 71(8_Supplement). 3295–3295. 4 indexed citations
12.
Bagri, Anil, Leanne Berry, Bert Gunter, et al.. (2010). Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy. Clinical Cancer Research. 16(15). 3887–3900. 110 indexed citations
13.
Belvin, Marcia, Leanne Berry, Julie Chan, et al.. (2010). 132 Intermittent dosing of the MEK inhibitor, GDC-0973, and the PI3K inhibitor, GDC-0941, results in prolonged accumulation of Bim and causes strong tumor growth inhibition in vivo. European Journal of Cancer Supplements. 8(7). 48–48. 4 indexed citations
14.
O’Brien, Carol, Jeffrey J. Wallin, Deepak Sampath, et al.. (2010). Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models. Clinical Cancer Research. 16(14). 3670–3683. 201 indexed citations
15.
Hoeflich, Klaus P., Carol O’Brien, Zachary Boyd, et al.. (2009). In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models. Clinical Cancer Research. 15(14). 4649–4664. 385 indexed citations
16.
Zha, Jiping, Carol O’Brien, Heidi Savage, et al.. (2009). Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Molecular Cancer Therapeutics. 8(8). 2110–2121. 66 indexed citations
17.
18.
Kasman, Ian, Anil Bagri, Judy Mak, et al.. (2008). Mechanistic evaluation of the combination effect of anti-VEGF and chemotherapy. Cancer Research. 68. 2494–2494. 3 indexed citations
19.
Berry, Leanne, Kai Barck, Mary Ann T. Go, et al.. (2008). Quantification of viable tumor microvascular characteristics by multispectral analysis. Magnetic Resonance in Medicine. 60(1). 64–72. 40 indexed citations
20.
Js, Greenberger, et al.. (1996). Stromal cell involvement in leukemogenesis and carcinogenesis.. PubMed. 10(1). 1–17. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jose Lobo Breakdown of academic impact, for papers by Teresa Klinowska Breakdown of academic impact, for papers by Yasir H. Ibrahim Breakdown of academic impact, for papers by Matthias Drosten Breakdown of academic impact, for papers by Ngocdiep T. Le Breakdown of academic impact, for papers by Michiya Nishino Breakdown of academic impact, for papers by Cornelia Quadt Breakdown of academic impact, for papers by Jiang Shou Breakdown of academic impact, for papers by Nandini Dey Breakdown of academic impact, for papers by Malte Peters
Rankless by CCL
2026